dpp-4 inhibitor and glp-1 receptor agonist combination not recommended ada Frontiers | inhibitors for treating T2DM Clinical Focus on GLP-1 Agonists
Description
10.1038/s41467-023-44067-4
New pharmaceuticals carry several risks some known, some still unknown
John M, Kalra S, Nair T
Lancet 2006;368:16961705 [DOI] [PubMed] [Google Scholar] 2.Nauck M
Another important factor is the patient's preference
3 What is GLP-1 and why it matters GLP-1 is an incretin hormone that is primarily secreted by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient ingestion, including carbohydrates, fats, and proteins
